Researchers developed plasma p-tau217–based clock models that estimate when cognitively unimpaired individuals with Alzheimer’s pathology may develop symptomatic disease. The models predicted symptom onset within about three to four years and may help improve clinical trial selection while remaining unsuitable for individual clinical decisions at present.